News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Cell Technology, Inc. Announces Orphan Drug Designation in the European Union for Rindopepimut, a Novel EGFRvIII Vaccine for Glioblastoma



10/31/2011 6:47:48 AM

NEEDHAM, Mass.--(BUSINESS WIRE)--Celldex Therapeutics, Inc. (Nasdaq: CLDX) today announced that the European Medicines Agency (EMA) has granted orphan drug designation for rindopepimut for the treatment of Glioblastoma (GB). GB is the most common and aggressive form of brain cancer. Rindopepimut is an immunotherapy that targets the tumor-specific oncogene (a growth promoter), EGFRvIII.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES